sintilimab

Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, West China Hospital, Sichuan University,

Abstract

Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,

Abstract

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.

Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Gansu Provincial Cancer Hospital,

Abstract

Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial.

Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China,

Abstract

Early clues in the battle against advanced gastric cancer: How plasma ctDNA signals the effectiveness of PD-1 inhibitors with chemotherapy.

Org: Gastric Cancer Center, The First Affiliated Hospital with Nanjing Medical University,

Abstract

Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Org: Key Laboratory of Cancer Prevention and Intervention, Zhejiang University College of Medicine, Colorectal Surgery and Oncology,

Abstract

PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).

Org: Department of Liver Surgery,

Abstract

Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).

Org: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Department of Urology, Southwest Hospital, Army Medical University, Chongqing, Chengdu, China, The First Affiliated Hospital of Kunming Medical University, Kunming, China,

Abstract

Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.

Org: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Liaoning Cancer Hospital, Liaoning, China, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, Department of Gynecologic Oncology, affiliated Cancer Hospital of Chonqing University, Chongqing, China, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China,

Abstract

Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.

Org: Department of Bone and Soft Tissue Tumor,

Abstract

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.

Org: The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,

Abstract

First-line immunochemotherapy modulates peripheral immune landscape in advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC): Prediction of response to combination therapy.

Org: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, Simcere Medical Laboratory Science Co., Ltd.,, State Key Laboratory of Neurology and Oncology Drug Development,

Abstract

Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.

Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,

Abstract

Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.

Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

Efficacy and safety of axitinib in combination with sintilimab as neoadjuvant therapy for patients with locally advanced renal cell carcinoma: A phase II clinical study.

Org: Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Combining nimotuzumab with PD-L1 inhibitors and chemotherapy to treat esophageal cancer: A retrospective study.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University,

Abstract

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

Org: Sun Yet Sen University Cancer Center,

Abstract

Sintilimab combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, multicenter, phase 2 trial.

Org: Meishan Hospital of Chinese medicine, Meishan, China, Nanbu Hospital of County Chinese medicine, Nanbu, China,

Abstract

A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.

Org: Peking University Shenzhen Hospital, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China, Beijing Biostar Pharmaceuticals,

Abstract

Efficacy and safety of transarterial therapy combined with donafenib plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Radiology, Hexian Hospital of Panyu District, Guangzhou, China, Department of Hepatobiliary Surgery, The First People’s Hospital of Foshan, Guangdong, China, Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,

Abstract

Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.

Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,

Abstract

First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.

Org: Shanghai Chest Hospital, Jiaotong University,

Abstract

Sintilimab and anlotinib combination therapy in PD-L1-positive recurrent/metastatic cervical carcinoma: A 3-year follow-up of ALTER-C201 study.

Org: Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,

Abstract

A phase I/II study of C019199 in combination with sintilimab in advanced malignancy.

Org: The First Affiliated Hospital of Xiamen University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,

Abstract

Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.

Org: 3rd Affiliated Hospital of ZhengZhou University,

Abstract

Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).

Org: Department of Respiratory Medicine,Taizhou Hosipital of Zhejiang Province, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, The Southwest Hospital of AMU,

Abstract

Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study.

Org: Innovent Biologics Co., Ltd.,

Clinical trial

Postoperative Adjuvant Immune Maintenance Therapy for High Recurrence Risk Esophageal Squamous Cell Carcinoma After Radical Resection: a Multicenter Randomized Controlled Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive Esophageal Squamous Cell Carcinoma After Radical Surgery Without Neoadjuvant Therapy

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined With Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients With Resectable and Borderline Resectable Pancreatic Cancer

Status: Not yet recruiting, Estimated PCD: 2025-10-01

Clinical trial

Epstein-Barr Virus DNA to Systemic Therapy for Treatment Adaptation in High Risk Nasopharyngeal Carcinoma (EP-STAR Trial) A Phase II, Multi-center, Biomarker-guided, Umbrella Trial

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

The Safety and Feasibility of Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Locally Advanced Resectable Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Efficacy and Safety of Sintilimab and Bevacizumab Biosimilar Combined With Pegylated Liposomal Doxorubicin in Pretreated Metastatic Triple-negative Breast Cancer: a Single Arm Phase II Trial

Status: Recruiting, Estimated PCD: 2025-03-15

Clinical trial

Efficacy and Safety of Conversion Therapy With Sintilimab in Combination With Chemotherapy and Apatinib in Patients With Stage IV Gastric Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Abstract

PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.

Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, Biotherapy Center,

Abstract

PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).

Org: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Guizhou Cancer Hospital, Guiyang, China, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Xijing Hospital, Xi'an, China,

Abstract

A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.

Org: Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences,

Abstract

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangzhou Institute of Respiratory Health, National Cancer Institute, Vilnius, Lithuania,

Abstract

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.

Org: Innovent Biologics, Inc.,

Abstract

Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.

Org: Peking University Cancer Hospital & Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Union Hospital Tongji Medical College Huazhong University of Science and Technology, The First Hospital with Nanjing Medical University Jiangsu Province Hospital,

Abstract

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Collaborative Innovation Center for Cancer Medicine,

Abstract

Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,

Abstract

Long-term outcome for patients with advanced non‒small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.

Org: Tianjin Medical University Cancer Institute and Hospital,

Abstract

Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Eastern Hepatobiliary Surgery Hospital, Shanghai Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,

Abstract

Efficacy and safety of first-line immunotherapy for advanced gastric or gastroesophageal cancer: System review network meta-analysis.

Org: Tianjin Medical University General Hospital, Tianjin, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,

Abstract

A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.

Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,

Abstract

Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.

Org: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Shanghai OrigiMed Co., Ltd, Shanghai, China, Shanghai OrigiMed Co., Ltd., Shanghai, China, Shanghai OrigiMed Co., Ltd., Cambridge, MA, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China,

Abstract

TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.

Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Fruquintinib plus sintilimab in patients with either treatment-naive or previously first line treated metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multicenter, single-arm phase 2 study.

Org: Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Hospital, Peking University First Hospital, Chongqing University Cancer Hospital, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China,

Abstract

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.

Org: School of Medicine, Nankai University, Tianjin, China, Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China, Department of Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, China, Department of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China,

Abstract

Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Safety and efficacy exploration of intraperitoneal perfusion of PD-1 monoclonal antibody for patients with primary liver cancer with malignant ascites: A prospective, single-arm, phase Ib clinical trial.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing Medical University, Research Institute of General Surgery, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,

Abstract

Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.

Org: Department of Liver Surgery & Transplantation Center, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China, Zhongshan Hospital Liver Cancer Institute, Shanghai, China, Department of Pathology，Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China,

Abstract

Association of neutrophil/lymphocyte ratio and IFN-γ with clinical response and survival in patients with MSS/pMMR mCRC treated with anti-PD-1 and VEGF inhibitors.

Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai Tenth People's Hospital Chongming Branch, Department of Oncology, Shanghai Tenth People's Hospital,

Abstract

Safety and clinical efficacy of sintilimab in pediatric patients with advanced or recurrent malignancies in a phase I study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, School of Medicine Nankai University,

Abstract

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).

Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,

Abstract

Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.

Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,

Abstract

TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Exploration of biomarkers in potentially resectable stage IIIB NSCLC patients receiving neoadjuvant chemoimmunotherapy.

Org: Department of Thoracic Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, Shenzhen, China, Department of Pathology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, Shenzhen, China, Geneplus-Beijing Institute, Beijing, China, Geneplus-Beijing, Beijing, Beijing, China,

Abstract

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: A retrospective study.

Org: Sichuan Cancer Hospital & Institute, Sichuan, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, School of Medicine, Zhejiang University, Hangzhou, China, University of Electronic Science and Technology of China,

Abstract

A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results.

Org: Harbin Medical University Cancer Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Beijing Chest Hospital,Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, West China Hospital, Sichuan University, Nanjing Drum Tower Hospital,

Product

sintilimab + anlotinib + metronomic chemotherapy

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10418

Clinical trial

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Intraperitoneal Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Status: , Estimated PCD: 2025-03-01